Premium
MYC protein expression is associated with poor prognosis in primary diffuse large B‐cell lymphoma of the central nervous system
Author(s) -
Tapia Gustavo,
Baptista MariaJoao,
MuñozMarmol AnaMaria,
Gaafar Ayman,
PuentePomposo Maria,
Garcia Olga,
MarginetFlinch Ruth,
Sanz Carolina,
Navarro JoseTomas,
Sancho JuanManuel,
Ribera JosepMaria,
Ariza Aurelio,
Mate JoseLuis
Publication year - 2015
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/apm.12390
Subject(s) - bcl6 , diffuse large b cell lymphoma , lymphoma , chromosomal translocation , immunophenotyping , immunohistochemistry , biology , cancer research , clinical significance , central nervous system , gene , pathology , b cell , medicine , antibody , immunology , flow cytometry , genetics , germinal center , neuroscience
MYC and BCL2 gene translocations and protein expression have recently demonstrated to be of prognostic significance in systemic diffuse large B‐cell lymphoma (DLBCL). However, their role in primary central nervous system DLBCL (CNS‐DLBCL) prognosis has been scarcely analyzed. We studied the immunophenotype, the status of the MYC , BCL2, and BCL6 genes and the clinical features of a series of 42 CNS‐DLBCL and evaluated their prognostic significance. We found high MYC protein expression in 43% of cases, and this was associated with lower overall survival (OS). Cases with concurrent expression of MYC and BCL2 showed a lower OS, although the difference did not reach statistical significance. Translocations involving the MYC or BCL2 genes were not detected. The BCL6 gene was frequently translocated, but was unrelated to survival. We conclude that MYC protein expression detected by immunohistochemistry identifies a CNS‐DLBCL subset with worse prognosis and may contribute to a more accurate risk stratification of CNS‐DLBCL patients.